Sign in
Taking peoplePhase 3

Two steroid treatment approaches for newly found heart sarcoidosis

Compares prednisone with methotrexate against prednisone alone in untreated cardiac sarcoidosis.

Key facts

Who runs it
Ottawa Heart Institute Research Corporation
Where
London, United KingdomSee the 2 sitesAlso in 4 other countries, 29 sites
Trial code
Registry title
Cardiac Sarcoidosis Randomized Trial
Status
Recruiting
Phase
Phase 3
People taking part
160 people, planned
Started
15 Jan 2019
Expected to end
Dec 2026
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Prednisone or Prednisolone
  • Methotrexate
Record updated
10 July 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with active cardiac sarcoidosis (sarcoidosis affecting the heart) who have not yet been treated. It compares low dose Prednisone plus Methotrexate with standard dose Prednisone.

Age
18 Years and older
Sex
All
Disease stage
Active cardiac sarcoidosis with heart problems: serious heart rhythm or conduction blocks (Mobitz II or third degree AV block), heart rate under 40bpm when awake, abnormal heart rhythms, LVEF < 50% or RVEF < 40%. No other explanation for these problems.
Earlier treatment
No current or recent (within two months) non-topical treatment for sarcoidosis. No current oral or IV treatment longer than 5 days. Not taking Methotrexate or Prednisone for another condition.
Biomarker or test result
FDG-PET scan within six months showing active disease, plus heart blood flow imaging. Also a positive sarcoid biopsy and/or a CT Chest showing lung sarcoidosis or swollen chest lymph nodes.

Main reasons for not taking part

  • Cannot take Methotrexate or Prednisone
  • Cannot have PET imaging, or severe fear of closed spaces
  • Pregnancy or breastfeeding
  • Women who can have children and refuse highly effective birth control
  • Already in another randomized clinical trial

The registry criteria, word for word

Show all 18 criteriaShow less

Who can take part

  • (i) Cardiac sarcoidosis presenting with one or more of the following clinical findings:
  • advanced conduction system disease (defined as Mobitz II AV block or third degree AV block)
  • significant sinus node dysfunction (defined as average HR less than 40bpm when awake and/or sustained atrial arrhythmias)
  • non- sustained or sustained ventricular arrhythmia
  • left ventricular dysfunction (LVEF < 50%)
  • right ventricular dysfunction (RVEF < 40%); AND; (ii) No alternative explanation for clinical features; AND; (iii) Nuclear Imaging within six-months of enrollment consisting of FDG-PET scan with FDG uptake suggestive of active CS and myocardial perfusion imaging; AND ONE OR BOTH OF FOLLOWING; (iv) Positive biopsy for Sarcoid (either EMB or extra-cardiac); (v) CT Chest showing features consistent with pulmonary sarcoidosis and/or mediastinal and/or hilar lymphadenopathy

Who cannot take part

  • Currently taking Methotrexate or Prednisone for another health condition
  • Pregnancy (all women of child bearing age and potential will have a negative BHCG test before enrollment)
  • Women of childbearing age who refuse to use a highly effective and medically acceptable form of contraception throughout the study
  • Current or recent (within two months) non-topical treatment for sarcoidosis
  • Current Oral/IV treatment of duration greater than 5 days
  • Intolerance or contra-indication to Methotrexate or Prednisone
  • Patient does not meet all of the above listed inclusion criteria
  • Patient is unable or unwilling to provide informed consent
  • Patient is included in another randomized clinical trial
  • Patient has a contraindication to PET imaging or is unlikely to tolerate due to severe claustrophobia
  • Breastfeeding
  • Patients for whom the investigator believes that the trial is not in the interest of the patient

Where in United Kingdom

Also in 4 other countries, 29 sites

  • Imperial College Healthcare Trust-NHS-Hammersmith HospitalLondon, United KingdomContact: Amanda Varnava, MDNot yet recruiting
  • King's College Hospital NHS Foundation TrustLondon, United KingdomContact: Francis D Murgatroyd, MDNot yet recruiting

About the trial

What the trial wants to find out

Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated.

Read full original descriptionShow less

The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).

The 2 groups in the trial

  • Prednisone (or Prednisolone)Existing treatment, for comparison

    \[Dose everywhere except Japan\] Prednisone 0.5 mg kg/day for 6 months (max dose 30 mg) \[Dose in Japan\] Prednisone or prednisolone 0.5 mg/kg po (max 30mg) for one month then reduce by 5 mg per month for five months

  • MethotrexateTreatment being tested

    \[Dose everywhere except Japan\] Methotrexate 15-20 mg orally, sc, or IM once a week for 6 months + Prednisone 20 mg po daily for one month then 10 mg po daily for one month then 5 mg po daily for one month and then stop. Also Folic Acid OD (exact dose and directions at physicians discretion) for 6 months. \[Dose in Japan\] Methotrexate 5-20mg mg orally, sc, or IM once a week for 6 months+ Prednisone or Prednisolone 20mg OD for 1 month then 10mg OD for 1 month then 5 mg OD one month. Also Folic Acid 2 mg po daily for 6 months.

    Treatment: Prednisone or Prednisolone and Methotrexate

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cardiac Sarcoidosis Multi-Center Randomized Controlled Trial
Plain-language title
Two steroid treatment approaches for newly found heart sarcoidosisGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Publications
Record updated
10 July 2026